Lipoic Acid for Progressive Multiple Sclerosis
(LAPMS Trial)

Recruiting in Palo Alto (17 mi)

+10 other locations

Overseen ByRebecca I. Spain, MD MSPH

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: VA Office of Research and Development

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.

Eligibility Criteria

This trial is for people with progressive forms of multiple sclerosis who can walk at least 20 meters without rest, even if they need walking aids. They must be able to consent and follow the study's procedures in English. It's not for those with other major diseases, pregnant or breastfeeding individuals, insulin-dependent diabetics, recent steroid users, or participants in a prior lipoic acid trial.

Inclusion Criteria

My MS is getting worse as defined by the study.

I can walk at least 20 meters without resting, with or without walking aids.

Exclusion Criteria

I can follow directions in English.

I have a health condition besides MS that affects my ability to walk.

I have used strong painkillers exceeding a certain dose for over 3 months in the past 2 years.

I need insulin for my diabetes or my diabetes is not controlled by pills.

I have been on scheduled steroids, either IV or oral, in the last year.

Participant Groups

The study aims to see if lipoic acid helps maintain mobility and brain health in progressive MS patients compared to a placebo. Participants will randomly receive either lipoic acid or an inactive substance (placebo) to assess the effectiveness of the treatment.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Arm 1: Lipoic AcidExperimental Treatment1 Intervention

59 subjects receive oral lipoic acid 1200mg daily

Group II: Arm 2: PlaceboPlacebo Group1 Intervention

59 subjects receive placebo daily